Do analysts recommend GRDX or ADCT?

ADC Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 503.86%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer VTVT or GRDX?

vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 51.08%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VTVT or GRDX more profitable?

vTv Therapeutics' return on equity of 3.96% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% Entero Therapeutics N/A -49.81% -11.02%

Do analysts prefer GRDX or OGI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate GNLX or GRDX?

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 526.52%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts clearly believe Genelux is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GNLX or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Entero Therapeutics N/A -49.81% -11.02%

Do analysts recommend GRDX or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Entero Therapeutics (GRDX) Competitors

$4.41 +0.08 (+1.85%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$4.53 +0.12 (+2.72%)

As of 06/26/2026 07:51 PM Eastern

Compare

GRDX vs. ADCT, VTVT, OGI, GNLX, and SPRO

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include ADC Therapeutics (ADCT), vTv Therapeutics (VTVT), Organigram Global (OGI), Genelux (GNLX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to ADC Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and ADC Therapeutics (NYSE:ADCT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Entero Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
ADC Therapeutics	-173.02%	N/A	-44.70%

In the previous week, ADC Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 6 mentions for ADC Therapeutics and 2 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.44 beat ADC Therapeutics' score of 0.11 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Positive
ADC Therapeutics	Neutral

ADC Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 503.86%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Entero Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	394.04	-$6.39M	-$1.88	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

ADC Therapeutics beats Entero Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

vTv Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

vTv Therapeutics' return on equity of 3.96% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Entero Therapeutics	N/A	-49.81%	-11.02%

In the previous week, vTv Therapeutics and vTv Therapeutics both had 2 articles in the media. vTv Therapeutics' average media sentiment score of 1.87 beat Entero Therapeutics' score of 1.44 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Very Positive
Entero Therapeutics	Positive

Entero Therapeutics has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	135.51	-$26.97M	-$0.93	N/A
Entero Therapeutics	$74.46K	394.04	-$6.39M	-$1.88	N/A

vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 51.08%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

vTv Therapeutics beats Entero Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Organigram Global?

Entero Therapeutics (NASDAQ:GRDX) and Organigram Global (NASDAQ:OGI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Entero Therapeutics has higher earnings, but lower revenue than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	394.04	-$6.39M	-$1.88	N/A
Organigram Global	$185.07M	0.78	-$17.70M	-$0.13	N/A

Entero Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Entero Therapeutics has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Organigram Global's return on equity of -13.41% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Organigram Global	-9.22%	-13.41%	-9.09%

In the previous week, Entero Therapeutics had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for Entero Therapeutics and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 1.89 beat Entero Therapeutics' score of 1.44 indicating that Organigram Global is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Organigram Global	Very Positive

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Organigram Global beats Entero Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Genelux has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

37.3% of Genelux shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 526.52%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts clearly believe Genelux is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Genelux and Genelux both had 2 articles in the media. Entero Therapeutics' average media sentiment score of 1.44 beat Genelux's score of 0.93 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Positive
Entero Therapeutics	Positive

Entero Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	12,882.53	-$32.15M	-$0.85	N/A
Entero Therapeutics	$74.46K	394.04	-$6.39M	-$1.88	N/A

Entero Therapeutics' return on equity of -49.81% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Genelux and Entero Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Spero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Entero Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	394.04	-$6.39M	-$1.88	N/A
Spero Therapeutics	$66.80M	1.96	$8.57M	$0.24	9.42

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Entero Therapeutics had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Entero Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.87 beat Entero Therapeutics' score of 1.44 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Spero Therapeutics	Very Positive

Spero Therapeutics has a net margin of 24.90% compared to Entero Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Spero Therapeutics	24.90%	35.58%	24.95%

Summary

Spero Therapeutics beats Entero Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$28.81M	$986.25M	$4.34B	$12.22B
Dividend Yield	N/A	4.84%	12.97%	6.13%
P/E Ratio	-2.35	1.50	22.01	24.18
Price / Sales	394.04	112.03	148.40	114.69
Price / Cash	N/A	20.06	38.27	54.37
Price / Book	0.59	8.05	13.62	6.36
Net Income	-$6.39M	-$3.78M	$115.37M	$337.99M
7 Day Performance	-18.33%	9.89%	0.82%	0.10%
1 Month Performance	-6.96%	0.87%	-2.50%	-0.11%
1 Year Performance	N/A	48.75%	10.80%	27.60%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	1.6399 of 5 stars	$4.41 +1.8%	N/A	N/A	$28.81M	$74.46K	N/A	9	Positive News Short Interest Decrease
ADCT ADC Therapeutics	3.3386 of 5 stars	$1.09 -0.5%	$6.25 +476.0%	-61.6%	$138.64M	$81.36M	N/A	310
VTVT vTv Therapeutics	2.44 of 5 stars	$35.04 flat	$53.00 +51.3%	+125.6%	$138.02M	$1.02M	N/A	9	News Coverage Negative News Gap Down
OGI Organigram Global	0.9992 of 5 stars	$0.96 flat	N/A	-26.4%	$135.80M	$185.07M	N/A	1,139	Positive News
GNLX Genelux	1.82 of 5 stars	$2.96 flat	$18.00 +508.1%	-5.8%	$132.95M	$8K	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. ADCT, VTVT, OGI, GNLX, and SPRO

How does Entero Therapeutics compare to ADC Therapeutics?

Summary

How does Entero Therapeutics compare to vTv Therapeutics?

Summary

How does Entero Therapeutics compare to Organigram Global?

Summary

How does Entero Therapeutics compare to Genelux?

Summary

How does Entero Therapeutics compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. ADCT, VTVT, OGI, GNLX, and SPRO

How does Entero Therapeutics compare to ADC Therapeutics?

Is GRDX or ADCT more profitable?

Does the media favor GRDX or ADCT?

Do analysts recommend GRDX or ADCT?

Which has higher earnings & valuation, GRDX or ADCT?

Do institutionals & insiders hold more shares of GRDX or ADCT?

Which has more risk and volatility, GRDX or ADCT?

Summary

How does Entero Therapeutics compare to vTv Therapeutics?

Which has more risk & volatility, VTVT or GRDX?

Is VTVT or GRDX more profitable?

Does the media prefer VTVT or GRDX?

Which has higher valuation and earnings, VTVT or GRDX?

Do analysts prefer VTVT or GRDX?

Do institutionals & insiders have more ownership in VTVT or GRDX?

Summary

How does Entero Therapeutics compare to Organigram Global?

Which has stronger earnings and valuation, GRDX or OGI?

Which has more risk and volatility, GRDX or OGI?

Do analysts prefer GRDX or OGI?

Is GRDX or OGI more profitable?

Does the media prefer GRDX or OGI?

Do institutionals and insiders believe in GRDX or OGI?

Summary

How does Entero Therapeutics compare to Genelux?

Which has more risk & volatility, GNLX or GRDX?

Do institutionals and insiders hold more shares of GNLX or GRDX?

Do analysts rate GNLX or GRDX?

Does the media refer more to GNLX or GRDX?

Which has stronger valuation & earnings, GNLX or GRDX?

Is GNLX or GRDX more profitable?

Summary

How does Entero Therapeutics compare to Spero Therapeutics?

Which has more volatility and risk, GRDX or SPRO?

Do institutionals & insiders hold more shares of GRDX or SPRO?

Which has stronger earnings & valuation, GRDX or SPRO?

Do analysts recommend GRDX or SPRO?

Does the media prefer GRDX or SPRO?

Is GRDX or SPRO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools